文献速递炎症性肠病消化道肿瘤与早癌

克罗恩病患者淋巴瘤风险随时间增加而溃疡性结肠炎患者未见增加:一项斯堪的纳维亚队列研究

Increasing Risk of Lymphoma Over Time in Crohn's Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-04-13

该研究基于瑞典和丹麦1969至2019年的登记数据,比较164,716例炎症性肠病(IBD)患者与1,639,027名匹配的普通人群参照个体,排除随访第一年后,采用Cox回归估计淋巴瘤亚型的风险比。结果显示克罗恩病(CD)患者淋巴瘤风险升高(HR 1.32;95%CI 1.16-1.50),溃疡性结肠炎(UC)患者风险轻度升高(HR 1.09;95%CI 1.00-1.20),但即使CD患者10年累积发病率差异也较低(0.08%;95%CI 0.02-0.13),且近20年HR升高与免疫调节剂和生物制剂使用增加同步。

要点

  • CD患者淋巴瘤风险升高(HR 1.32;95%CI 1.16-1.50),UC患者风险轻度升高(HR 1.09;95%CI 1.00-1.20)。
  • 即使CD患者,10年累积发病率差异也较低(0.08%;95%CI 0.02-0.13)。
  • 近20年HR升高,与免疫调节剂和生物制剂使用增加同步;联合治疗或二线生物制剂暴露者HR最高,但未暴露者HR也升高。

核心结论

  • 过去20年间,CD患者淋巴瘤风险增加,而UC患者未增加,主要由T细胞淋巴瘤和侵袭性B细胞淋巴瘤驱动。

研究设计与样本

  • 瑞典和丹麦两国基于登记的队列研究,1969年至2019年,比较164,716例IBD患者与1,639,027名匹配的普通人群参照个体,采用Cox回归估计淋巴瘤亚型的风险比,排除随访第一年。

主要发现

  • 1969年至2019年,CD患者258例、UC患者479例及匹配参照个体6675例发生淋巴瘤。
  • CD患者淋巴瘤发病率为35/10万人年,UC患者为34/10万人年,匹配参照个体分别为28/10万人年和33/10万人年。
  • CD患者淋巴瘤风险升高(HR 1.32;95%CI 1.16-1.50),UC患者风险轻度升高(HR 1.09;95%CI 1.00-1.20)。
  • 即使CD患者,10年累积发病率差异也较低(0.08%;95%CI 0.02-0.13)。
  • 近20年HR升高,与同期免疫调节剂和生物制剂使用增加相对应;CD和UC患者侵袭性B细胞非霍奇金淋巴瘤HR升高,CD患者T细胞非霍奇金淋巴瘤HR升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Earlier studies have provided varying risk estimates for lymphoma in patients with inflammatory bowel disease (IBD), but often have been limited by detection biases (especially during the first year of follow-up evaluation), misclassification, and small sample size; and rarely reflect modern-day management of IBD. METHODS: We performed a binational register-based cohort study (Sweden and Denmark) from 1969 to 2019. We compared 164,716 patients with IBD with 1,639,027 matched general population reference individuals. Cox regression estimated hazard ratios (HRs) for incident lymphoma by lymphoma subtype, excluding the first year of follow-up evaluation. RESULTS: From 1969 to 2019, 258 patients with Crohn's disease (CD), 479 patients with ulcerative colitis (UC), and 6675 matched reference individuals developed lymphoma. This corresponded to incidence rates of 35 (CD) and 34 (UC) per 100,000 person-years in IBD patients, compared with 28 and 33 per 100,000 person-years in their matched reference individuals. Although both CD (HR, 1.32; 95% CI, 1.16-1.50) and UC (HR, 1.09; 95% CI, 1.00-1.20) were associated with an increase in lymphoma, the 10-year cumulative incidence difference was low even in CD patients (0.08%; 95% CI, 0.02-0.13). HRs have increased in the past 2 decades, corresponding to increasing use of immunomodulators and biologics during the same time period. HRs were increased for aggressive B-cell non-Hodgkin lymphoma in CD and UC patients, and for T-cell non-Hodgkin lymphoma in CD patients. Although the highest HRs were observed in patients exposed to combination therapy (immunomodulators and biologics) or second-line biologics, we also found increased HRs in patients naïve to such drugs. CONCLUSIONS: During the past 20 years, the risk of lymphomas have increased in CD, but not in UC, and were driven mainly by T-cell lymphomas and aggressive B-cell lymphomas.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Olén O, Smedby KE, Erichsen R, et al. Increasing Risk of Lymphoma Over Time in Crohn's Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study. Clin Gastroenterol Hepatol. 2023. PMID: 37061104. doi:10.1016/j.cgh.2023.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。